Seeking Alpha
 

Bio-Reference Laboratories, Inc. (BRLI)

- NASDAQ
  • Aug. 28, 2014, 12:46 PM
    | Comment!
  • Aug. 26, 2014, 5:35 PM
    | Comment!
  • Jun. 5, 2014, 3:53 PM
    • Shares of BioReference Laboratories (BRLI +20.6%) jump on a 5x surge in volume in response to its fiscal Q2 earnings report.
    • Net revenues: $201.4M (+14.1%); operating income: $18.9M (-8.7%); net income: $10.3M (-8.8%); EPS: $0.37 (-9.8%); cash & equiv: $24.5M (+36.1%).
    • Revenue/patient: $84.18 (-0.9%).
    | Comment!
  • Jun. 5, 2014, 12:49 PM
    | 2 Comments
  • Dec. 19, 2013, 5:38 PM
    | Comment!
  • Nov. 27, 2013, 2:04 PM
    • BioReference Laboratories (BRLI -20.8%) plunges after providing Q4 and FY13 guidance.
    • "Despite continued strong volume growth, the Company believes there is an ongoing recalibration of reimbursement for the industry, which has resulted in substantial downward pressure from many payers regarding reimbursement," the company says, adding that it has "had to negotiate contract modifications to reimbursement rates, conditions of payment and / or eligibility with dozens of health plans representing a substantial numbers of lives nationwide."
    • Q4 patient volume seen at +15% Y/Y. Q4 revenue per patient for non-genetic test seen -4% versus Q3.
    • Q4 outlook: $0.40/share on revenue of $192M.
    • FY outlook: $1.65/share.
    • BLRI also says it "expects that guidance for 2014 will call for an increase in net revenues of 10%, an increase in patient volume of 10% and an increase in net income of 10%." (PR)
    | Comment!
  • Nov. 27, 2013, 12:45 PM
    | Comment!
  • Aug. 29, 2013, 11:18 AM
    • Bio-Reference Labs (BRLI +3%) moves up on a solid FQ3 earnings beat today.
    • Total revenue rose to $185,427, +16% from the same quarter last year and the highest recorded in a quarter in corporate history.
    • Net income increased by 17%.
    • Revenue per patient was $85.25, an increase of 7% over the $79.75 in the prior year.
    | Comment!
  • Aug. 21, 2013, 3:42 PM
    • While correlation doesn't necessarily imply causation, it's probably worth noting that today's action in shares of Neogenomics (NEO -8.4%) mirrors the stock's dismal performance from last Tuesday.
    • The connection: Peer BioReference Laboratories (BRLI +2.5%) announced "strategic acquisitions" both today and on August 13.
    | 3 Comments
  • Aug. 13, 2013, 3:15 PM
    • BioReference Laboratories (BRLI +2%) acquires most of Hunter Laboratories' assets, giving BRLI a West Cost presence and Medi-Cal in-network status.
    • "Having a local base for operations can provide significant operational and logistical synergies," CEO Marc Grodman notes. (PR)
    • Shares of Neogenomics (NEO -7.8%), a notable peer, are off sharply on the session.
    | Comment!
  • Jul. 10, 2013, 12:55 PM
    More on William Blair's Bio-Reference (BRLI -8.8%) downgrade: A push for lower payment rates for lab tests could disproportionately hurt BRLI due to its exposure to blood-based cancer tests — rates for lymphoma tests could rise 70% or more, analysts say. Also moving on the news is Quest Diagnostics (DGX +1.4%) which William Blair thinks will be the least affected, while shares of Neogenomics (NEO -15.4%) plummet on above average volume.
    | Comment!
  • Jul. 10, 2013, 12:45 PM
    Midday top 10 gainers: NEON +25%. INO +22%. NUS +15%. SKBI +14%. PCYC +13%. VRML +13%. BMJ +13%. MCP +13%. ADHD +11%. SPEX +11%.
    Midday top 10 Losers: ADVS -25%. NEO -17%. PME -14%. XNY -11%. CREG -11%. ALJ -9%. TRR -8%. RAX -8%. BRLI -8%. LCNB -8%.
    | Comment!
  • Jul. 10, 2013, 12:16 PM
    Bio-Reference Laboratories (BRLI -8.1%) slips on a downgrade to Market Perform from Outperform at William Blair.
    | Comment!
  • Feb. 28, 2013, 12:33 PM
    Bio-Reference Laboratories (BRLI +5.8%) shrugs off a negative article in The Street Sweeper yesterday to trade higher in spite posting a mixed FQ1 earnings report. The company beat on a per share basis but missed on its top line consensus as revenue was impacted from hurrican Sandy. Going forward the company reaffirms its guidance for FY13, still expecting net revenues to increase more than 15% and net income to increase by approximately 20%.
    | Comment!
  • Feb. 27, 2013, 3:24 PM
    Bio-Reference Labs (BRLI -0.6%) slips on a negative article from short-seller The Street Sweeper. The gist of the article says that the company is likely to be faced with a flood of denials from some of the largest health insurance companies in the country, and that growth projections are overly optimistic.
    | 3 Comments
  • Dec. 6, 2012, 3:35 PM
    Bio-Reference Laboratories (BRLI +5%) moves up after reporting a largely in-line FQ4, but a 16% Y/Y jump in total revenue. Net profit also rose 23%, as the company again recorded strong revenue growth, despite the impact of Hurricane Sandy on the Northeast regional provider of diagnostic testing for physicians. Revenue per patient rose 4% in the latest quarter, while the number of patients served rose 12%.
    | 1 Comment
Visit Seeking Alpha's
BRLI vs. ETF Alternatives
Company Description
Bio-Reference Laboratories Inc is engaged in providing laboratory testing services. The Company offers chemical diagnostic tests including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis and toxicology.